Homeostatic Neural Plasticity

Definition

Homeostatic neural plasticity is the source’s model of compensatory changes that keep neural circuits from remaining excessively active or inactive, including adjustments in postsynaptic receptor availability and excitability.

Current Synthesis

The Science & Treatment of Bipolar Disorder describes homeostatic plasticity as a stabilizing process: prolonged circuit activity can lead postsynaptic cells to reduce receptor availability, while prolonged underactivity can lead them to add receptors. The episode uses this model to contrast two source-reported psychiatric mechanisms. Lithium is described as gradually reducing postsynaptic excitability, while ketamine is described as increasing it in the context of depression.

The durable concept is circuit compensation, not a simple claim that excitation is bad or good. Bipolar states, depression, drug effects, cell type, circuit, dose, and timing all matter, and the episode does not turn receptor scaling into a diagnostic marker or self-treatment rule.

Key Claims

• Neural circuits can compensate for sustained overactivity or underactivity rather than remaining fixed.
• Postsynaptic receptor removal and addition are presented as two candidate mechanisms for stabilizing activity.
• The episode places lithium and ketamine on different excitability branches without treating them as interchangeable.
• A circuit-level mechanism does not by itself determine diagnosis, medication selection, dose, or treatment response.
• Homeostatic plasticity links cellular adaptation to psychiatry while remaining broader than bipolar disorder.

Evidence

• Circuit compensation: The Science & Treatment of Bipolar Disorder says overly active circuits may reduce postsynaptic receptors and underactive circuits may add them.
• Lithium branch: The Science & Treatment of Bipolar Disorder describes lithium as reducing postsynaptic excitability over time in its bipolar-treatment account.
• Ketamine branch: The Science & Treatment of Bipolar Disorder describes ketamine as increasing postsynaptic excitability in its depression-treatment account.
• Clinical boundary: The Science & Treatment of Bipolar Disorder repeatedly places psychiatric treatment under qualified medical supervision.

Counterevidence & Qualifications

The source gives an educational mechanism model rather than a complete account of synaptic scaling, receptor subtypes, intracellular signaling, circuit specificity, or clinical response. Its lithium and ketamine contrast is not evidence that one scalar measure of excitability explains mania, depression, or treatment choice. Ketamine’s reported antidepressant effect is described as potent but transient and requiring supervised repeat treatment.

What Changed

• Created a circuit-stability concept from the full episode’s receptor-scaling and psychiatric-treatment discussion.

Related Concepts

• Lithium Bipolar Treatment - medication branch linked to reduced postsynaptic excitability and neuroprotection in the source.
• Bipolar Disorder - clinical context in which the mechanism is introduced.
• Bipolar Interoception Decline - complementary internal-state and connectivity mechanism branch.
• Circuit-Based Psychiatry - broader framework connecting symptoms and interventions to network function.
• Psychiatric Medication Supervision Boundary - clinical boundary preventing mechanism claims from becoming self-treatment instructions.